ABSTRACT

INTRODUCTION. Medications with chondroprotective effects are used in the treatment of osteoarthritis.

AIM. To conduct a comparative analysis and characterize drugs with chondroprotective properties.

MATERIALS AND METHODS. The search was conducted for the period from 2000 to 2024 in the PubMed and E-library scientific electronic library database by keywords: «symptom-modifying», «structural-modifying», «disease-modifying», «osteoarthritis», «multicentre double-blind randomized study», «chondroitin sulfate», «glucosamine sulfate», «undenatured collagen type II», «avocado-soybean unsaponifiables», «diacerein», «glycosaminoglycan-peptide complex», «bioactive concentrate of small marine fish», as well as on the database websites The Ministry of Health of the Russian Federation is a rubricator of clinical recommendations for the keywords: «gonarthrosis», «coxarthrosis», and the State Register of Medicines. The articles in which a systematic review and meta-analysis (9 articles), randomized clinical trials (10 articles), clinical recommendations (10 articles) and conclusions of leading experts in the field under study (7 articles) are analyzed.

CONCLUSION. These drugs have different characteristics and levels of evidence. Preference in the treatment of patients with osteoarthritis should be given to drugs with symptomatic and structural-modifying effects – chondroitin sulfate and glucosamine sulfate. This position is reflected in the updated clinical guidelines of the Russian Ministry of Health. In 2024, the new «Coxarthrosis 2024» and «Gonarthrosis 2024» control centers of the Ministry of Health of Russia were approved. The regulator's position on the use of chondroitin sulfate and glucosamine sulfate coincides with the opinion of international medical communities and experts, which is reflected in international clinical guidelines for choosing treatment tactics for patients with osteoarthritis.

KEYWORDS: chondroitin sulfate, glucosamine sulfate, undenatured type II collagen, diacerein, avocado-soybean unsaponifiables, Chondroguard, ChondroguardTRIO

For citation: Shavlovskaya O.A. Comparative Analysis of Drugs with Chondroprotective Effect: a Review. Comorbidity Neurology. 2025; 2 (1): 49-55. https://doi.org/10.62505/3034-185x-2025-2-1-49-55

For correspondence: Olga A. Shavlovskaya, Dr. Sci. (Med.), Professor, Chair of Organization of Medical Rehabilitation and Sanatorium Treatment, International University of Restorative Medicine, Moscow, Russia, e-mail: shavlovskaya@1msmu.ru

REFERENCES

1.Рубрикатор клинических рекомендаций. Коксартроз. 2024. URL: https://cr.minzdrav.gov.ru/preview-cr/870_1 (дата обращения 24.01.2025)

2.Рубрикатор клинических рекомендаций. Гонартроз. 2024. URL: https://cr.minzdrav.gov.ru/preview-cr/868_1 (дата обращения 24.01.2025)

3.Kolasinski S., Neogi T., Hochberg M., et al. 2019 American College of Rheumatology / Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72 (2): 149-62. https://doi.org/10.1002/acr.24131

4.Kloppenburg M., Kroon F., Blanco F., et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019; 78 (1): 16-24. https://doi.org/10.1136/annrheumdis-2018-213826

5.Smolen J., Landewe R., Bijlsma J., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79 (6): 685-99. https://doi.org/10.1136/annrheumdis-2019-216655

6.Bruyere O., Honvo G., Veronese N., et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49 (3): 337-350. https://doi.org/10.1016/j.semarthrit.2019.04.008

7. Arden N.K., Perry T.A., Bannuru R.R., et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nature Reviews Rheumatology. 2020;17(1): 59-66. https://doi.org/10.1038/s41584-020-00523-9 

8.Geenen R., Overman C.L., Christensen R., et al. EULAR recommendations for the health professional’s approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77(6):797-807. https://doi.org/10.1136/annrheumdis-2017-212662

9.Moseng T., Vliet Vlieland T.P.M, Battista S., et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update. Ann Rheum Dis. 2024; 83 (6): 730-740. https://doi.org/10.1136/ard-2023-225041

10.Shavlovskaya O.A., Gromova О.А., Kochish A.Yu., et al. Disease-modifying osteoarthritis drugs (DMOADs): new trends in osteoarthritis therapy. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023; 16 (3): 482-499. https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.207 (In Russ.)

11.Shavlovskaya O.A., Sarvilina I.V., Gromova O.A. et al. Pharmacotherapy of pain in musculoskeletal diseases: evolution and revolution of views. Neurology, Neuropsychiatry, Psychosomatics. 2022; 14 (4): 87–95. https://doi.org/10.14412/2074-2711-2022-4-87-95 (In Russ.)

12.Shavlovskaya O.A., Gromova О.А., Torshin I.Yu., Romanov I.D. From misconceptions to reasonable osteoarthritis patients therapy. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023; 16 (2): 317-330. https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.183 (In Russ.)

13.Railhac J-J., Zaim M., Saurel A-S., et al. Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: a randomized, double-blind, placebo-controlled pilot study using MRI. Clinical Rheumatology. 2012; 31 (9): 1347-1357. https://doi.org/10.1007/s10067-012-2022-4

14.Morita M., Yamada K., Date H., et al. Efficacy of chondroitin sulfate for painful knee osteoarthritis: a one-year, randomized, double-blind, multicenter clinical study in Japan. Biological and Pharmaceutical Bulletin. 2018; 41 (2): 163-171. https://doi.org/10.1248/bpb.b17-00556

15.Simental-Mendia M., Sanchez-Garcia A., Vilchez-Cavazos F., et al. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials. Rheumatology International. 2018; 38 (8): 1413-1428. https://doi.org/10.1007/s00296-018-4077-2  

16.Rabade A., Viswanatha G.L., Nandakumar K., Kishore A. Evaluation of efficacy and safety of glucosamine sulfate, chondroitin sulfate, and their combination regimen in the management of knee osteoarthritis: a systematic review and meta-analysis. Inflammopharmacology. 2024; 32 (3): 1759-1775. https://doi.org/10.1007/s10787-024-01460-9

17.Richy F., Bruyere O., Ethgen O., et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis. Archives of Internal Medicine. 2003; 163 (13): 1514. https://doi.org/10.1001/archinte.163.13

18.Torshin I.Yu., Lila A.M., Naumov A.V., et al. Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020; 13 (4): 388-399. https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.066 (In Russ.)

19.    Minasov T.B., Lila A.M., Nazarenko A.G. et al. Morphological reflection of highly purified chondroitin sulfate action in patients with decompensated form of knee osteoarthritis. Modern Rheumatology Journal. 2022; 16 (6): 55–63. https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.06610.14412/1996-7012-2022-6-55-63 (In Russ.)

20.Minasov T.B., Lila A.M., Nazarenko A.G., et al. Stratification of decompensated osteoarthritis and modern options of the preoperative therapy using Chondroguard® based on pheno- and endotyping. Russian Medical Inquiry. 2023; 7 (3): 124-136 https://doi.org/10.32364/2587-6821-2023-7-3-124-136 (In Russ.)

21.Sadigursky D., Magnavita V.F.S, Sá C.K.C, et al. Undenatured collagen type II for the treatment of osteoarthritis of the knee. Acta Ortop Bras. 2022; 30 (2): e240572. https://doi.org/10.1590/1413-785220223002240572

22.Schön C., Knaub K., Alt W., et al. UC-II undenatured type II collagen for knee joint flexibility: a multicenter, randomized, double-blind, placebo-controlled clinical study. J Integr Complement Med. 2022; 28 (6): 540-548. https://doi.org/10.1089/jicm.2021.0365

23.Kumar P., Bansal P., Rajnish R.K., et al. Efficacy of undenatuder collagen in knee osteoarthritis: review of efficacy the literature with limited meta-analysis. Am J Transl Res. 2023;15 (9): 5545-5555

24.Stabile M., Girelli C.R., Lacitignola L., et al. 1H-NMR metabolomic profile of healthy and osteoarthritic canine synovial fluid before and after UC-II supplementation. Sci Rep. 2022; 12 (1): 19716. https://doi.org/10.1038/s41598-022-23977-1

25.Martinez-Puig D., Costa-Larrión E., Rubio-Rodríguez N., Gálvez-Martín P. Collagen supplementation for joint health: the link between composition and scientific knowledge Nutrients. 2023; 15 (6): 1332. https://doi.org/10.3390/nu15061332

26.Shiojima Y., Takahashi M., Takahashi R., et al. Efficacy and safety of dietary undenatured type II collagen on joint and motor function in healthy volunteers: a randomized, double-blind, placebo-controlled, parallel-group study. J Am Nutr Assoc. 2022; 12 (7): 1-18. https://doi.org/10.1080/07315724.2021.2024466

27. Gromova O.A., Torshin I.Yu., Lila A.M. About the use of chondroitin sulfate, glucosamine sulfate and undenatured type II collagen for back and limb pain and osteoarthritis. Neurology, Neuropsychiatry, Psychosomatics. 2022; 14 (6): 122-130. https://doi.org/10.14412/2074-2711-2022-6-122-130 (In Russ.)

28.Dougados M., Nguyen M., Berdah L., et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum. 2001; 44 (11): 2539-47. https://doi.org/10.1002/1529-0131(200111)44:11<2539::aid-art434>3.0.co;2-t

29.Pelletier J.P., Raynauld J.P., Dorais M., et al. An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. DISSCO Trial Investigator Group. Rheumatology (Oxford). 2020; 59 (12): 3858-3868. https://doi.org/10.1093/rheumatology/keaa072

30.Zeng F., Wang K., Duan H., et al. Diacerein versus non‑steroidal anti‑inflammatory drugs in the treatment of knee osteoarthritis: a meta‑analysis. Journal of Orthopaedic Surgery and Research. 2023; 18: 308. https://doi.org/10.1186/s13018-023-03786-6

31.Pavelka K, Gatterova J.V., Gollerova V. et al. A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon) as a structure modifying therapy in osteoarthritis of the hip and knee. Osteoarthritis Cartilage. 2000; 8 (5): 335-42. https://doi.org/10.1053/joca.1999.0307 

32.Maheu E., Cadet C., Marty M. et al. Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Ann Rheum Dis. 2014; 73 (2): 376-384. https://doi.org/10.1136/annrheumdis-2012-202485

33.Simental-Mendia M., Sanchez-Garcia A., Acosta-Olivo C.A., et al. Efficacy and safety of avocado-soybean unsaponifiables for the treatment of hip and knee osteoarthritis: A systematic review and metaanalysis of randomized placebo-controlled trials. Int J Rheum Dis. 2019; 22 (9): 1607-1615. https://doi.org/10.1111/1756-185X.13658

34.Lambert C., Bellemere G., Boyer G. et al. Composition analysis and pharmacological activity of avocado/soybean unsaponifiable products used in the treatment of osteoarthritis. Front Pharmacol. 2022: 12: 781389. https://doi.org/10.3389/fphar.2021.781389

35. Karateev A.E., Lila A.M. Therapeutic potential of a drug based on avocado and soy unsaponifiable compounds in the treatment of osteoarthritis: data from Russian and international studies (descriptive review). Modern Rheumatology Journal. 2022;16 (2): 48-55. https://doi.org/10.14412/1996-7012-2022-2-48-55 (In Russ)

36.Анатомо-терапевтическо-химическая (АТХ) система классификации с установленными суточными дозами. Всемирная Организация Здравоохранения; 12.27.2024. Доступно по: https://atcddd.fhi.no/atc_ddd_index 25.01.2025

ADDITIONAL INFORMATION

Olga A. Shavlovskaya, Dr. Sci. (Med.), Professor, Chair of Organization of Medical Rehabilitation and Sanatorium Treatment, University of Restorative Medicine, Moscow, Russia. E-mail: shavlovskaya@1msmu.ru. ORCID: https://orcid.org/0000-0003-3726-0730

Author contributions. Author confirms their authorship according to the ICMJE criteria (author contributed significantly to the conception, study design and preparation of the article, read and approved the final version before publication). Shavlovskaya O.A. – conceptualization, methodology, formal analysis, investigation, writing – original draft, writing – review & editing.

The content is available under the Creative Commons Attribution 4.0 License.

©2025. Olga A. Shavlovskaya